HH160

China-based Huahui Health has granted BeOne Medicines (Nasdaq: ONC) a global exclusive option over HH160, a preclinical trispecific antibody targeting PD-1, CTLA-4, and VEGF-A simultaneously, in a cancer immunotherapy collaboration that carries a headline value of up to USD 2.02 billion. Under the agreement, BeOne Medicines (NASDAQ: ONC) pays an upfront USD 20 million to secure the option, with a further USD 100 million due upon formal exercise. Huahui Health, a privately held Beijing-based biopharmaceutical company founded in 2015, retains ownership of the asset through the option period. BeOne — formerly BeiGene, redomiciled to Switzerland and rebranded in 2025 — would receive global rights to develop, manufacture, and commercialize HH160 upon option exercise. Beyond the exercise payment, Huahui Health is eligible for up to USD 1.9 billion in development, regulatory, and commercial milestones, plus tiered royalties on net sales. The parties also agreed to discuss BeOne’s potential participation in Huahui Health’s future financing activities, though no equity terms were confirmed. HH160 is described by Huahui Health as a symmetrical hexavalent trispecific antibody engineered on its proprietary PolyBoost multispecific antibody platform. The molecule simultaneously engages three targets: PD-1 and CTLA-4, both co-inhibitory receptors whose blockade restores and amplifies T cell anti-tumor activity, and VEGF-A, a pro-angiogenic cytokine whose neutralization can starve tumors of blood supply and may enhance immune infiltration of the tumor microenvironment. A 2025 AACR abstract — titled “A symmetrical hexavalent trispecific antibody, HH160, targeting PD-1, CTLA-4 and VEGF-A for enhanced anti-cancer effects” — represents the only public scientific disclosure for the asset, confirming its preclinical stage. No clinical trial identifier, IND filing, or regulatory designation has been publicly disclosed for HH160 in any jurisdiction. The individual targets are well validated across approved therapies, and bispecific antibodies combining two of the three axes are in active clinical development. Akeso’s cadonilimab targets PD-1 and CTLA-4, while ivonescimab addresses PD-1 and VEGF. HH160’s trispecific format, combining all three in a single symmetrical molecule, has no direct approved or late-stage equivalent in the public domain. The PolyBoost platform’s symmetrical architecture is intended to address a core engineering challenge in multispecific antibody design: maintaining binding affinity, molecular stability, and manufacturability across all three arms simultaneously. A symmetrical hexavalent format — two binding sites per target — preserves avidity at each individual target without the chain-mispairing risks associated with asymmetric heterodimerization strategies used by competing platforms. For BeOne, the transaction adds a multispecific immunotherapy asset to a hematology and solid tumor portfolio built primarily around small molecules and conventional monoclonal antibodies. The option structure limits near-term financial exposure while securing global exclusivity on an asset whose clinical profile remains to be established. BeOne’s decision to exercise — and commit the USD 100 million exercise payment — will depend on data generated during the option period. Huahui Health’s pipeline context gives the HH160 deal additional framing. In January 2026, China’s National Medical Products Administration granted conditional approval to Libevitug injection, the company’s first commercial product, for chronic hepatitis D infection in adults. Libevitug, a human monoclonal antibody targeting the PreS1 domain of the HBV and HDV envelope protein that blocks viral entry into hepatocytes, was approved in China in January 2026 and holds Breakthrough Therapy Designation from the US FDA, with a global Phase III trial underway. The HH160 collaboration represents Huahui Health’s move to monetize its oncology pipeline alongside its established hepatology franchise, using an out-licensing model that preserves internal resources while accessing BeOne’s global development infrastructure. The content above comes from the network. if any infringement, please contact us to modify.

Total global revenues of $1.5 billion for the first quarter, an increase of 35% from the prior year Foundational BRUKINSA (zanubrutinib) global revenues of $1.1 billion for the first quarter, an increase of 38% from the prior year Diluted GAAP Earnings per American Depository Share (ADS) of $1.96 for the first quarter; non-GAAP diluted Earnings per ADS of $3.24 for the first quarter SAN CARLOS, Calif.--(BUSINESS WIRE)-- $ONC #BeOne -- BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the first quarter of 2026. John V. Oyler, Co-Founder, Chairman, and CEO, BeOne, said: “These strong first-quarter results reinforce BeOne’s continued growth as a global oncology leader, driven by disciplined commercial execution, and underpinned by our established hematology leadership, and an impressive, rapidly emerging solid tumor pipeline. The sustained competitive advantages of our global superhighway for clinical development and manufacturing are now clear. BRUKINSA has firmly established itself as the foundational, best-in-class BTK inhibitor with unmatched long-term efficacy and safety data for the treatment of CLL and as the only BTKi with proven efficacy superiority over ibrutinib which has resulted in clear global revenue leadership. The fixed-duration combination of sonrotoclax, a foundational, next-generation BCL2 inhibitor, and BRUKINSA represents a potential new standard-of-care in first-line CLL, with BTK CDAC BGB-16673 emerging as a potential first-in-class therapy in the relapsed or refractory setting. With more than 20 abstracts across our hematology and solid tumor pipeline accepted for presentation at ASCO, BeOne has solidified its position as a leading oncology company.” (Amounts in thousands of U.S. dollars and unaudited) Three Months Ended March 31, 2026 2025 % Change Net product revenues $ 1,487,329 $ 1,108,530 34 % Other revenue $ 26,109 $ 8,749 198 % Total revenue $ 1,513,438 $ 1,117,279 35 % GAAP income from operations $ 249,902 $ 11,102 2,151 % Adjusted income from operations* $ 414,394 $ 139,357 197 % GAAP net income $ 227,357 $ 1,270 17,802 % Adjusted net income* $ 375,042 $ 136,137 175 % GAAP basic EPS per ADS $ 2.05 $ 0.01 20,400 % Adjusted basic EPS per ADS* $ 3.38 $ 1.27 166 % GAAP diluted EPS per ADS $ 1.96 $ 0.01 19,500 % Adjusted diluted EPS per ADS* $ 3.24 $ 1.22 166 % Free Cash Flow* $ 160,547 $ (12,325 ) 1,403 % * For an explanation of our use of non-GAAP financial measures, refer to the “Note Regarding Use of Non-GAAP Financial Measures” section later in this press release and for a reconciliation of each non-GAAP financial measure to the most comparable GAAP measures, see the table at the end of this press release. First Quarter 2026 Financial Results Product Revenue totaled $1.5 billion for the first quarter of 2026, representing growth of 34% compared to the prior-year period. BRUKINSA: Global sales totaled $1.1 billion for the first quarter of 2026, representing growth of 38% compared to the prior-year period; U.S. sales of BRUKINSA totaled $761 million in the first quarter of 2026, representing growth of 35% compared to the prior-year period. TEVIMBRA (tislelizumab): Global sales totaled $206 million in the first quarter of 2026, representing growth of 20% compared to the prior-year period. Amgen in-licensed products: Global sales totaled $142 million in the first quarter of 2026, representing growth of 25% compared to the prior-year period. Gross Margin as a percentage of global product sales for the first quarter of 2026 was 89%, compared to 85% in the prior-year period on a GAAP basis. The gross margin percentage increased due to a proportionally higher sales mix of global BRUKINSA compared to other products in our portfolio. Gross margin also benefited from productivity improvements resulting in lower costs for both BRUKINSA and TEVIMBRA. Operating Expenses The following table summarizes operating expenses for the first quarter of 2026: GAAP Non-GAAP (unaudited, in thousands, except percentages) Q1 2026 Q1 2025 % Change Q1 2026 Q1 2025 % Change Research and development $ 541,224 $ 481,887 12 % $ 465,904 $ 421,195 11 % Selling, general and administrative $ 555,097 $ 459,288 21 % $ 471,993 $ 395,511 19 % Total operating expenses $ 1,096,321 $ 941,175 16 % $ 937,897 $ 816,706 15 % Research and Development (R&D) Expenses increased for the first quarter of 2026 compared to the prior-year period on both a GAAP and adjusted basis due to advancing preclinical programs into the clinic and early clinical programs into late stage. Selling, General and Administrative (SG&A) Expenses increased for the first quarter of 2026 compared to the prior-year period on both a GAAP and adjusted basis due to continued investment to support commercial growth. SG&A expenses as a percentage of product sales were 37% for the first quarter of 2026, compared to 41% in the prior-year period. Net Income and Basic/Diluted Earnings Per Share GAAP net income for the first quarter of 2026 was $227 million, an increase of $226 million over the prior-year period, primarily attributable to revenue growth and improved operating leverage. For the first quarter of 2026, basic and diluted earnings per share were $0.16 and $0.15 per share and $2.05 and $1.96 per American Depositary Share (ADS), compared to basic and diluted earnings per share of $0.00 per share and $0.01 per ADS in the prior-year period. Free Cash Flow for the first quarter of 2026 was $161 million, representing an increase of $173 million over the prior-year period. For further details on BeOne’s First Quarter 2026 Financial Statements, please see BeOne’s Quarterly Report on Form 10-Q for the first quarter of 2026 filed with the U.S. Securities and Exchange Commission. Updated Full Year 2026 Guidance BeOne’s financial guidance is summarized below: Prior FY 2026 Guidance Current FY 2026 Guidance 1 Total revenue $6.2 - $6.4 billion $6.3 - $6.5 billion GAAP gross margin % High-80% range High-80% range GAAP operating expenses 2 (combined R&D and SG&A) $4.7 - $4.9 billion $4.7 - $4.9 billion GAAP operating income 2 $700 - $800 million $750 - $850 million Non-GAAP operating income 2,3 $1.4 - $1.5 billion $1.45 - $1.55 billion 1 Assumes May 1, 2026 foreign exchange rates. 2 Does not assume any potential new, material business development activity or unusual/non-recurring items. 3 Non-GAAP operating income is a financial measure that excludes from the corresponding GAAP measure costs related to share-based compensation, depreciation and amortization expense. Guidance assumes that Non-GAAP expenses track overall expense growth. BeOne’s total revenue guidance for full year 2026 of $6.3 billion to $6.5 billion includes expectations for strong revenue growth driven by BRUKINSA’s leadership position in the U.S. and continued global expansion in both Europe and other important rest of world markets. Gross margin percentage is expected to be in the high-80% range and includes the impact of product mix and a full year of 2026 productivity improvements. Guidance for combined operating expenses on a GAAP basis includes expectations of investment to support growth in both commercial and research at a pace that continues to deliver meaningful operating leverage. The Company is providing the following additional guidance on items impacting net income and earnings per ADS: Other income (expense) : Estimated range of $25 million to $50 million in expense, includes interest amortization from Royalty Pharma arrangement. Income tax outlook : Earnings may provide sufficient positive evidence to reverse certain valuation allowances in 2026, resulting in a material tax benefit when recognized; the timing and magnitude of a potential reversal is uncertain; prior to reversal, income tax expense should trend with earnings per historical relationship. See Form 10-Q for additional updates on income tax uncertainties. Diluted ADS outstanding : The Company expects diluted ADSs outstanding of approximately 118 million. First Quarter 2026 Business Highlights Core Marketed Products BRUKINSA (zanubrutinib) Received Orphan Drug Designation in Japan for the treatment of adult patients with relapsed or refractory (R/R) marginal zone lymphoma (MZL). Submitted New Drug Application in Japan for R/R MZL and tablet formulation. Sonrotoclax (BCL2 inhibitor) Launched and commercially available in China for the treatment of adult patients with R/R mantle cell lymphoma (MCL) and R/R chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Included in the European Society of Medical Oncology (ESMO) guidelines as a recommended third-line treatment for R/R MCL patients. TEVIMBRA (tislelizumab) Received acceptance of a Supplemental Biologics License Application (sBLA) by the U.S. Food and Drug Administration (FDA) with Priority Review for the treatment of adult patients with first-line HER2-positive gastroesophageal adenocarcinoma (GEA) in combination with ZIIHERA (zanidatamab) and chemotherapy, based on results of the HERIZON-GEA-01 trial which demonstrated statistically significant and clinically meaningful improvement in overall survival versus trastuzumab plus chemotherapy. Received acceptance of sBLA by the Center for Drug Evaluation (CDE) in China for the treatment of adult patients with first-line HER2-positive GEA in combination with ZIIHERA and chemotherapy. ZIIHERA (zanidatamab) Received acceptance of sBLA by the CDE in China for the treatment of adult patients with first-line HER2-positive GEA in combination with chemotherapy, with or without TEVIMBRA. Select Clinical-Stage Programs Hematology BGB-16673 (BTK CDAC): Initiated Phase 2 cohorts in R/R MZL and Richter’s Transformation. Breast and Gynecological Cancers BGB-43395 (CDK4 inhibitor): Received acceptance of Phase 1 study data as a poster presentation at ASCO. BG-C9074 (B7-H4 ADC): Received acceptance of Phase 1 study data as a rapid oral presentation at ASCO. Gastrointestinal Cancers BGB-B2033 (GPC3x41BB bispecific antibody): Received FDA Orphan Drug Designation for hepatocellular carcinoma (HCC). Initiated potentially registrational study in patients with HCC. Received acceptance of Phase 1 study data as a rapid oral presentation at ASCO. Lung Cancer BG-C0979 (ADAM9-targeting ADC): Initiated first-in-human study. Inflammation and Immunology BG-A3004 (KLRG1 mAb): Initiated first-in-human study. Anticipated R&D Milestones Programs Milestones Timing BRUKINSA • Interim analysis in the Phase 3 MANGROVE study data in combination with rituximab versus bendamustine plus rituximab for the treatment of adult patients with first-line MCL. 1H 2026 • Japan regulatory action for the treatment of adult patients with first-line gastric cancer. 1H 2026 • U.S. FDA regulatory action for the treatment of adult patients with first-line HER2-positive GEA in combination with ZIIHERA. 2H 2026 TEVIMBRA • China regulatory action for the treatment of adult patients with first-line HER2-positive GEA in combination with ZIIHERA. 1H 2027 Hematology • Sonrotoclax (BCL2 inhibitor): ◦ FDA regulatory action on New Drug Application as monotherapy treatment of adult patients with R/R MCL. 1H 2026 ◦ Phase 3 study initiation for the treatment of adult patients with R/R multiple myeloma t(11;14). 2H 2026 • BGB-16673 (BTK CDAC): ◦ Phase 2 potential accelerated approval submission (if data support) for the treatment of adult patients with R/R CLL. 2H 2026 Breast/Gynecologic • BGB-43395 (CDK4 inhibitor): Cancers ◦ Phase 3 study initiation for the treatment of adult patients with first-line HR-positive, HER2-negative metastatic breast cancer. 1H 2026 Lung Cancer • BON-110 (PD-1xVEGF-AxCTLA-4 trispecific antibody): ◦ First-in-human study initiation. 1H 2026 Gastrointestinal • BGB-B2033 (GPC3x41BB bispecific antibody): Cancers ◦ Pivotal Phase 3 study initiation. 2H 2026 Inflammation and • BGB-16673 (BTK CDAC): Immunology ◦ Phase 2 study initiation for the treatment of adult patients with chronic spontaneous urticaria. 2H 2026 Corporate Updates Entered into an exclusive option with Huahui Health to license worldwide rights to HH160 (BON-110), a novel trispecific antibody targeting PD-1, VEGF-A and CTLA-4. BeOne’s Earnings Results Webcast The Company’s earnings conference call for the first quarter 2026 will be broadcast via webcast at 8:00 a.m. ET on Wednesday, May 6, 2026, and will be accessible through the Investors section of BeOne’s website at . Supplemental information in the form of a slide presentation, transcript of prepared remarks, and a replay of the webcast will also be available. About BeOne BeOne Medicines is a global oncology company that is discovering and developing innovative treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The Company has a growing global team spanning six continents who are driven by scientific excellence and exceptional speed to reach more patients than ever before. To learn more about BeOne, please visit and follow us on LinkedIn , X , Facebook and Instagram . Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding: BeOne’s continued growth as a global oncology leader; the fixed-duration combination of sonrotoclax and BRUKINSA as a potential new standard-of-care in first-line CLL; the emergence of BGB-16673 as a potential first-in-class therapy for R/R CLL; BeOne’s future revenue, gross margin percentage, operating expenses, operating income, other income or expense, income tax and diluted ADS outstanding; BeOne’s expectations regarding continued global expansion and investment to support growth; upcoming R&D milestones to be achieved by BeOne; the timing of clinical and regulatory developments and data readouts; and BeOne’s plans, commitments, aspirations and goals under the caption “About BeOne.” Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeOne’s ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; BeOne’s ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeOne’s ability to obtain and maintain protection of intellectual property for its medicines and technology; BeOne’s reliance on third parties to conduct drug development, manufacturing, commercialization, and other services; BeOne’s limited experience in obtaining regulatory approvals and commercializing pharmaceutical products; BeOne’s ability to obtain additional funding for operations and to complete the development of its drug candidates and achieve and maintain profitability; and those risks more fully discussed in the section entitled “Risk Factors” in BeOne’s most recent periodic report filed with the U.S. Securities and Exchange Commission (“SEC”), as well as discussions of potential risks, uncertainties, and other important factors in BeOne’s subsequent filings with the SEC. All information in this press release is as of the date of this press release, and BeOne undertakes no duty to update such information unless required by law. BeOne’s financial guidance is based on estimates and assumptions that are subject to significant uncertainties. Condensed Consolidated Statements of Operations (U.S. GAAP) (Amounts in thousands of U.S. dollars, except for shares, American Depositary Shares (ADSs), per share and per ADS data) Three Months Ended March 31, 2026 2025 (Unaudited) Revenues Product revenue, net $ 1,487,329 $ 1,108,530 Other revenue 26,109 8,749 Total revenues 1,513,438 1,117,279 Cost of sales - products 167,215 165,002 Gross profit 1,346,223 952,277 Operating expenses: Research and development 541,224 481,887 Selling, general and administrative 555,097 459,288 Total operating expenses 1,096,321 941,175 Income from operations 249,902 11,102 Interest income 27,664 12,850 Interest expense (32,887 ) (7,002 ) Other income, net 14,536 3,950 Income before income taxes 259,215 20,900 Income tax expense 31,858 19,630 Net income $ 227,357 $ 1,270 Earnings per share Basic $ 0.16 $ 0.00 Diluted $ 0.15 $ 0.00 Weighted-average shares outstanding—basic 1,442,451,870 1,390,052,966 Weighted-average shares outstanding—diluted 1,505,027,338 1,445,253,219 Earnings per American Depositary Share (“ADS”) Basic $ 2.05 $ 0.01 Diluted $ 1.96 $ 0.01 Weighted-average ADSs outstanding—basic 110,957,836 106,927,151 Weighted-average ADSs outstanding—diluted 115,771,334 111,173,325 Select Condensed Consolidated Balance Sheet Data (U.S. GAAP) (Amounts in thousands of U.S. Dollars) As of March 31, December 31, 2026 2025 (unaudited) (audited) Assets: Cash, cash equivalents and restricted cash $ 4,853,425 $ 4,609,647 Accounts receivable, net 938,019 865,080 Inventories 681,590 608,227 Property, plant and equipment, net 1,640,918 1,641,678 Total assets $ 8,553,619 $ 8,188,573 Liabilities and equity: Accounts payable $ 423,546 $ 479,035 Accrued expenses and other payables 1,079,283 1,109,120 R&D cost share liability 35,700 64,345 Sale of future royalty liability 904,399 906,956 Debt 1,078,655 1,019,206 Total liabilities 3,793,177 3,827,379 Total equity $ 4,760,442 $ 4,361,194 Select Condensed Consolidated Statements of Cash Flows (U.S. GAAP) (Amounts in thousands of U.S. Dollars) Three Months Ended March 31, 2026 2025 (unaudited) Cash, cash equivalents and restricted cash at beginning of period $ 4,609,647 $ 2,638,747 Net cash provided by operating activities 201,336 44,082 Net cash used in investing activities (45,510 ) (121,941 ) Net cash provided by (used in) financing activities 68,632 (33,777 ) Net effect of foreign exchange rate changes 19,320 3,480 Net increase (decrease) in cash, cash equivalents, and restricted cash 243,778 (108,156 ) Cash, cash equivalents and restricted cash at end of period $ 4,853,425 $ 2,530,591 Note Regarding Use of Non-GAAP Financial Measures BeOne provides certain non-GAAP financial measures, including Adjusted Operating Expenses, Adjusted Operating Loss, Adjusted Net Income, Adjusted Earnings Per Share, Free Cash Flow and certain other non-GAAP income statement line items, each of which include adjustments to GAAP figures. These non-GAAP financial measures are intended to provide additional information on BeOne’s operating performance. Adjustments to BeOne’s GAAP figures exclude, as applicable, non-cash items such as share-based compensation, depreciation and amortization. Certain other special items or substantive events may also be included in the non-GAAP adjustments periodically when their magnitude is significant within the periods incurred. Non-GAAP adjustments are tax effected to the extent there is U.S. GAAP current tax expense. The Company currently records a valuation allowance on its net deferred tax assets, so there is no net impact recorded for deferred tax effects. BeOne maintains an established non-GAAP policy that guides the determination of what costs will be excluded in non-GAAP financial measures and the related protocols, controls and approval with respect to the use of such measures. BeOne believes that these non-GAAP financial measures, when considered together with the GAAP figures, can enhance an overall understanding of BeOne’s operating performance. The non-GAAP financial measures are included with the intent of providing investors with a more complete understanding of BeOne’s historical and expected financial results and trends and to facilitate comparisons between periods and with respect to projected information. In addition, these non-GAAP financial measures are among the indicators BeOne’s management uses for planning and forecasting purposes and measuring BeOne’s performance. These non-GAAP financial measures should be considered in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. The non-GAAP financial measures used by BeOne may be calculated differently from, and therefore may not be comparable to, non-GAAP financial measures used by other companies. RECONCILIATION OF SELECTED GAAP MEASURES TO NON-GAAP MEASURES (Amounts in thousands of U.S. Dollars, except for per share and per ADS data) (unaudited) Three Months Ended March 31, 2026 2025 Reconciliation of GAAP to adjusted cost of sales - products: GAAP cost of sales - products $ 167,215 $ 165,002 Less: Depreciation 4,326 2,613 Less: Amortization of intangibles 1,742 1,173 Adjusted cost of sales - products $ 161,147 $ 161,216 Reconciliation of GAAP to adjusted research and development: GAAP research and development $ 541,224 $ 481,887 Less: Share-based compensation cost 53,856 41,767 Less: Depreciation 21,464 18,925 Adjusted research and development $ 465,904 $ 421,195 Reconciliation of GAAP to adjusted selling, general and administrative: GAAP selling, general and administrative $ 555,097 $ 459,288 Less: Share-based compensation cost 69,492 53,684 Less: Depreciation 13,595 10,076 Less: Amortization of intangibles 17 17 Adjusted selling, general and administrative $ 471,993 $ 395,511 Reconciliation of GAAP to adjusted operating expenses GAAP operating expenses $ 1,096,321 $ 941,175 Less: Share-based compensation cost 123,348 95,451 Less: Depreciation 35,059 29,001 Less: Amortization of intangibles 17 17 Adjusted operating expenses $ 937,897 $ 816,706 Reconciliation of GAAP to adjusted income from operations: GAAP income from operations $ 249,902 $ 11,102 Plus: Share-based compensation cost 123,348 95,451 Plus: Depreciation 39,385 31,614 Plus: Amortization of intangibles 1,759 1,190 Adjusted income from operations $ 414,394 $ 139,357 Reconciliation of GAAP to adjusted net income: GAAP net income $ 227,357 $ 1,270 Plus: Share-based compensation expenses 123,348 95,451 Plus: Depreciation 39,385 31,614 Plus: Amortization of intangibles 1,759 1,190 Plus: Impairment of equity investments — 12,376 Plus: Discrete tax items 3,535 5,473 Plus: Income tax effect of non-GAAP adjustments 1 (20,342 ) (11,237 ) Adjusted net income $ 375,042 $ 136,137 Reconciliation of GAAP to adjusted EPS - basic GAAP earnings per share - basic $ 0.16 $ 0.00 Plus: Share-based compensation expenses 0.09 0.07 Plus: Depreciation 0.03 0.02 Plus: Amortization of intangibles 0.00 0.00 Plus: Impairment of equity investments 0.00 0.01 Plus: Discrete tax items 0.00 0.00 Plus: Income tax effect of non-GAAP adjustments 1 (0.01 ) (0.01 ) Adjusted earnings per share - basic $ 0.26 $ 0.10 Reconciliation of GAAP to adjusted EPS - diluted GAAP earnings per share - diluted $ 0.15 $ 0.00 Plus: Share-based compensation expenses 0.08 0.07 Plus: Depreciation 0.03 0.02 Plus: Amortization of intangibles 0.00 0.00 Plus: Impairment of equity investments 0.00 0.01 Plus: Discrete tax items 0.00 0.00 Plus: Income tax effect of non-GAAP adjustments 1 (0.01 ) (0.01 ) Adjusted earnings per share - diluted $ 0.25 $ 0.09 Reconciliation of GAAP to adjusted earnings per ADS - basic GAAP earnings per ADS - basic $ 2.05 $ 0.01 Plus: Share-based compensation expenses 1.11 0.89 Plus: Depreciation 0.35 0.30 Plus: Amortization of intangibles 0.02 0.01 Plus: Impairment of equity investments 0.00 0.12 Plus: Discrete tax items 0.03 0.05 Plus: Income tax effect of non-GAAP adjustments 1 (0.18 ) (0.11 ) Adjusted earnings per ADS - basic $ 3.38 $ 1.27 Reconciliation of GAAP to adjusted earnings per ADS - diluted GAAP earnings per ADS - diluted $ 1.96 $ 0.01 Plus: Share-based compensation expenses 1.07 0.86 Plus: Depreciation 0.34 0.28 Plus: Amortization of intangibles 0.02 0.01 Plus: Impairment of equity investments 0.00 0.11 Plus: Discrete tax items 0.03 0.05 Plus: Income tax effect of non-GAAP adjustments 1 (0.18 ) (0.10 ) Adjusted earnings per ADS - diluted $ 3.24 $ 1.22 1. Tax effect of Non-GAAP adjustments is based on the statutory tax rate in the relevant tax jurisdiction. Please note that the Company currently records a valuation allowance on its net deferred tax assets, so there is no net impact recorded for deferred tax effects. Contacts Investor Contact Liza Heapes +1 857-302-5663 ir@beonemed.com Media Contact Kyle Blankenship +1 667-351-5176 media@beonemed.com Read full story here